Siegfried Holding
SFZN.SW Mid CapHealthcare · Drug Manufacturers - Specialty & Generic
Mis à jour: Aug 2, 2026, 22:14 UTC
Price Chart
Indicateurs clés
Valuation Analysis
About the Company
Siegfried Holding en bref
Siegfried Holding (SFZN.SW) is currently trading at 75,75 CHF with a market capitalization of 2,9 Md €. The trailing P/E ratio stands at 19.73x, with a forward P/E of 16.06x. The 52-week range spans from 65,05 CHF to 101,60 CHF ; the current price is 25.4% below the yearly high. Year-over-year revenue growth stands at +5.0%. The net profit margin stands at 12.7%.
💰 Dividende
Siegfried Holding pays an annual dividend of 0,40 CHF per share, representing a yield of 0.53%. The payout ratio stands at 9.9%.
📊 Avis des analystes
12 analystes évaluent Siegfried Holding (SFZN.SW) au consensus : Acheter. L'objectif de cours moyen est de 98,17 CHF , soit un potentiel de +29.59% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 75,00 CHF à 130,00 CHF .
Siegfried Holding : la thèse d'investissement en détail
Siegfried Holding (SFZN.SW) operates in the Healthcare — specifically Drug Manufacturers - Specialty & Generic — and is headquartered in Switzerland. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.
Le scénario haussier
Wall Street consensus sits at Buy with an average price target implying roughly 29.59% upside from current levels — analyst sentiment is firmly constructive.
Valorisation en contexte
The PEG ratio at 1.44 sits in the reasonable zone — the price tag is roughly aligned with the company's growth profile, neither punishing nor euphoric.
À surveiller
- The forward P/E of 16.06x is meaningfully below the trailing 19.73x — analysts expect earnings to step up; the next earnings release is the test.
- The analyst consensus price target implies 29.59% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.
Thèse d'investissement : forces et faiblesses
- Rentabilité élevée des capitaux propres (15.98% ROE)
- Consensus des analystes : Buy
- –Free cash flow négatif
Aperçu technique
The price is in a transition zone relative to the moving averages — no clear signal.
Profil de risque
The data points to relatively defensive market behavior.
Trading Data
💵 Dividend Info
Related Stocks in the Same Sector
More Santé stocks
Top peers in the same sector — ranked by market cap.
Where can I buy Siegfried Holding?
Compare top-rated brokers — low fees, trusted providers, fully regulated.
📊 Plutôt un fonds qu’une action isolée ? Comparatif d’ETF :
Live Market Data
Real-time chart, financials, earnings, analysts, insider trades, events & news
